glp-1 drugs and lupus Glucagon-like peptide-1 receptor agonist nephritis in systemic lupus erythematosus with type 2 diabetes Do SGLT2 and GLP-1 therapies
Description
In patients with type 2 diabetes, however, this balance breaks down
doi: 10.1002/dmrr.553
Ans: Ozempic dominated with approximately 35.12% share in 2025
doi: 10.1111/liv.14385
New horizons
& Wong, V
